From a clinical perspective, we here propose to pharmacologically manipulate CD8+ CAR T cell metabolism during the in vitro expansion phase and prior to their injection into patients to confer on these cells a superior and long-lasting motility capacity while at the same time avoiding any possible alterations on tumor cell metabolism, which could unintentionally promote tumor growth. The gene discussed is CD8A; the disease is neoplasm.